LUDG Files Genomic Patent AI Uncovers Differentially Expressed Genes

Ludwig Enterprises Files Cancer Genomic Patent

Machine Learning AI Uncovers Differentially Expressed Genes

SPARKS, NV / ACCESSWIRE / May 9, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company™) is pleased to announce that recently analyzed genomic mRNA data has revealed differentially expressed genes when comparing tissue from patients with bladder, breast, and colon cancer. This data has been added to a provisional patent previously filed on September 20, 2022.

Described in the patent application is Ludwig's, mRNA Inflammatory Index™ microarray technology, which measures 48 different cytokine and chemokine biomarkers of inflammation within noninvasively obtained patient cheek cells. Analysis of cancer patient data with machine learning AI revealed statistically significant expression levels for specific cytokines and chemokines when comparing 3 different cancers, bladder, breast, and colon.

"These dramatic genomic mRNA findings are a significant discovery for our company as well as for patients afflicted with cancer," said Dr. Marvin S. Hausman MD, the developer of the mRNA Inflammatory Index™, and Chairman of the Scientific Advisory Board of Ludwig. "This genomic language combined with AI may allow doctors to classify cancer on a molecular basis for better diagnostic and prognostic precision, and also design personalized therapies tailored to the individual."

Additional applications for Ludwig's mRNA biomarker technology may include uses in drug and nutraceutical research and development. mRNA biomarkers already play a significant role in the development and approval process for these products. "On average around 65% of drug approvals by EMA and FDA between 2015 and 2019 have been associated with incorporation of at least 1 biomarker in the development program and higher percentage of biomarker acceptance is expected in the near future" (Gromova M, et al. 2020. Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomarker Insights. 15: 1-15).

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc. is a healthcare holding company focused on innovative mRNA genomic technology, therapeutics, and nutraceuticals. Through its subsidiary Precision Genomics, it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and possibly prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent scientific research published articles into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc.